MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cancers14184385

Медицинская библиотека · Cancers · 2022

Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases.

Amanullah Ayeman, Upadhyay Arun, Dhiman Rohan, Singh Sarika, Kumar Amit, Ahirwar Dinesh Kumar, Gutti Ravi Kumar, Mishra Amit

СтатьяОбзорПеревод в очереди

Аннотация

Diclofenac is a highly prescribed non-steroidal anti-inflammatory drug (NSAID) that relieves inflammation, pain, fever, and aches, used at different doses depending on clinical conditions. This drug inhibits cyclooxygenase-1 and cyclooxygenase-2 enzymes, which are responsible for the generation of prostaglandin synthesis. To improve current diclofenac-based therapies, we require new molecular systematic therapeutic approaches to reduce complex multifactorial effects. However, the critical challenge that appears with diclofenac and other drugs of the same class is their side effects, such as signs of stomach injuries, kidney problems, cardiovascular issues, hepatic issues, and diarrhea. In this article, we discuss why defining diclofenac-based mechanisms, pharmacological features, and its medicinal properties are needed to direct future drug development against neurodegeneration and imperfect ageing and to improve cancer therapy. In addition, we describe various advance molecular mechanisms and fundamental aspects linked with diclofenac which can strengthen and enable the better designing of new derivatives of diclofenac to overcome critical challenges and improve their applications.

Для цитирования: Amanullah Ayeman, Upadhyay Arun, Dhiman Rohan, Singh Sarika, Kumar Amit, Ahirwar Dinesh Kumar, Gutti Ravi Kumar, Mishra Amit. Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases.. Cancers. 2022. DOI: 10.3390/cancers14184385.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.